339 related articles for article (PubMed ID: 25425420)
1. Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum.
Banda NK; Mehta G; Chao Y; Wang G; Inturi S; Fossati-Jimack L; Botto M; Wu L; Moghimi SM; Simberg D
Part Fibre Toxicol; 2014 Nov; 11():64. PubMed ID: 25425420
[TBL] [Abstract][Full Text] [Related]
2. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.
Inturi S; Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D
ACS Nano; 2015 Nov; 9(11):10758-68. PubMed ID: 26488074
[TBL] [Abstract][Full Text] [Related]
3. Complement opsonization of nanoparticles: Differences between humans and preclinical species.
Li Y; Wang G; Griffin L; Banda NK; Saba LM; Groman EV; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2021 Oct; 338():548-556. PubMed ID: 34481928
[TBL] [Abstract][Full Text] [Related]
4. Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking.
Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D
Front Immunol; 2016; 7():418. PubMed ID: 27777575
[TBL] [Abstract][Full Text] [Related]
5. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.
Banda NK; Levitt B; Wood AK; Takahashi K; Stahl GL; Holers VM; Arend WP
Clin Exp Immunol; 2010 Jan; 159(1):100-8. PubMed ID: 19843088
[TBL] [Abstract][Full Text] [Related]
6. High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties.
Wang G; Inturi S; Serkova NJ; Merkulov S; McCrae K; Russek SE; Banda NK; Simberg D
ACS Nano; 2014 Dec; 8(12):12437-49. PubMed ID: 25419856
[TBL] [Abstract][Full Text] [Related]
7. Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions.
Harboe M; Garred P; Borgen MS; Stahl GL; Roos A; Mollnes TE
Clin Exp Immunol; 2006 Jun; 144(3):512-20. PubMed ID: 16734621
[TBL] [Abstract][Full Text] [Related]
8. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.
Gifford G; Vu VP; Banda NK; Holers VM; Wang G; Groman EV; Backos D; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2019 May; 302():181-189. PubMed ID: 30974134
[TBL] [Abstract][Full Text] [Related]
9. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population.
Benasutti H; Wang G; Vu VP; Scheinman R; Groman E; Saba L; Simberg D
Bioconjug Chem; 2017 Nov; 28(11):2747-2755. PubMed ID: 29090582
[TBL] [Abstract][Full Text] [Related]
10. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.
Hamad I; Hunter AC; Szebeni J; Moghimi SM
Mol Immunol; 2008 Dec; 46(2):225-32. PubMed ID: 18849076
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of the lectin pathway of complement in human serum.
Roos A; Bouwman LH; Munoz J; Zuiverloon T; Faber-Krol MC; Fallaux-van den Houten FC; Klar-Mohamad N; Hack CE; Tilanus MG; Daha MR
Mol Immunol; 2003 Jan; 39(11):655-68. PubMed ID: 12493641
[TBL] [Abstract][Full Text] [Related]
12. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo.
Chen F; Wang G; Griffin JI; Brenneman B; Banda NK; Holers VM; Backos DS; Wu L; Moghimi SM; Simberg D
Nat Nanotechnol; 2017 May; 12(4):387-393. PubMed ID: 27992410
[TBL] [Abstract][Full Text] [Related]
13. Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging.
Unterweger H; Janko C; Schwarz M; Dézsi L; Urbanics R; Matuszak J; Őrfi E; Fülöp T; Bäuerle T; Szebeni J; Journé C; Boccaccini AR; Alexiou C; Lyer S; Cicha I
Int J Nanomedicine; 2017; 12():5223-5238. PubMed ID: 28769560
[TBL] [Abstract][Full Text] [Related]
14. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
Inada K
Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
[TBL] [Abstract][Full Text] [Related]
15.
Wang G; Griffin JI; Inturi S; Brenneman B; Banda NK; Holers VM; Moghimi SM; Simberg D
Front Immunol; 2017; 8():151. PubMed ID: 28239384
[TBL] [Abstract][Full Text] [Related]
16. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
[TBL] [Abstract][Full Text] [Related]
17. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization.
Rohrer B; Coughlin B; Kunchithapautham K; Long Q; Tomlinson S; Takahashi K; Holers VM
Mol Immunol; 2011 Mar; 48(6-7):e1-8. PubMed ID: 21257205
[TBL] [Abstract][Full Text] [Related]
18. Human L-ficolin, a recognition molecule of the lectin activation pathway of complement, activates complement by binding to pneumolysin, the major toxin of Streptococcus pneumoniae.
Ali YM; Kenawy HI; Muhammad A; Sim RB; Andrew PW; Schwaeble WJ
PLoS One; 2013; 8(12):e82583. PubMed ID: 24349316
[TBL] [Abstract][Full Text] [Related]
19. Binding to complement factors and activation of the alternative pathway by Acanthamoeba.
Pumidonming W; Walochnik J; Dauber E; Petry F
Immunobiology; 2011; 216(1-2):225-33. PubMed ID: 20627448
[TBL] [Abstract][Full Text] [Related]
20. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma.
Skliris A; Happonen KE; Terpos E; Labropoulou V; Børset M; Heinegård D; Blom AM; Theocharis AD
Eur J Immunol; 2011 Feb; 41(2):437-49. PubMed ID: 21268013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
